Fate Therapeutics, Inc(NASDAQ:FATE) 
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, ...
Website: http://www.fatetherapeutics.com
Founded: 2007
Full Time Employees: 178
Sector: Healthcare
Industry: Biotechnology
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 0.69
H 0.76
L 0.66
C 0.75
V 3,604,642
10EMA 0.75
20EMA 0.75
60EMA 0.75
120EMA 0.75
250EMA 0.75